{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:35:10Z","timestamp":1788226510222,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Office of the Assistant Secretary for Preparedness and Response","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>\n            Gepotidacin is a first-in-class triazaacenaphthylene antibacterial that inhibits bacterial type II topoisomerases and has\n            <jats:italic>in vitro<\/jats:italic>\n            activity against a range of bacterial pathogens, including\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            . Urinary tract infections often progress to pyelonephritis and are a worldwide problem due to the prevalence of multidrug-resistant\n            <jats:named-content content-type=\"genus-species\">E. coli<\/jats:named-content>\n            strains.\n          <\/jats:p>","DOI":"10.1128\/aac.00086-19","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T14:42:44Z","timestamp":1556808164000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of Human Exposures of Gepotidacin (GSK2140944) against\n            <i>Escherichia coli<\/i>\n            in a Rat Pyelonephritis Model"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-7541","authenticated-orcid":false,"given":"Jennifer L.","family":"Hoover","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Singley","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Elefante","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Rittenhouse","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00468-17"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1112933"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02095-16"},{"key":"e_1_3_3_8_2","article-title":"O05.3 A phase II, randomised, study in adult subjects evaluating the efficacy, safety, and tolerability of single doses of gepotidacin (GSK2140944) for treatment of uncomplicated urogenital gonorrhea","volume":"93","author":"Perry C","year":"2017","unstructured":"Perry C, Dumont E, Perry C, Raychaudhuri A. 2017. O05.3 A phase II, randomised, study in adult subjects evaluating the efficacy, safety, and tolerability of single doses of gepotidacin (GSK2140944) for treatment of uncomplicated urogenital gonorrhea. Sex Transm Infect 93:A11.","journal-title":"Sex Transm Infect"},{"key":"e_1_3_3_9_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Hossain M","year":"2014","unstructured":"Hossain M, Tiffany CA, McDonald M, Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944: a novel bacterial topoisomerase inhibitor, poster F-276. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC."},{"key":"e_1_3_3_10_2","volume-title":"ASM Microbe","author":"VanScoy BD","year":"2017","unstructured":"VanScoy BD, Lakota EA, Conde H, Elefante PB, Bhavnani SM, Scangarella-Oman NE, Ambrose PG. 2017. Characterization of pharmacokinetics-pharmacodynamics for efficacy of gepotidacin (GSK2140944) against Escherichia coli in an in vitro infection model, poster. ASM Microbe, New Orleans, LA."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3791\/54649"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0174-3031(84)80025-6"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.33.4.408"},{"key":"e_1_3_3_14_2","first-page":"531","article-title":"The therapeutic response of cephalosporin-treated Escherichia coli pyelonephritis of the rat, in relation to variations of the infection model","volume":"259","author":"Schulz E","year":"1985","unstructured":"Schulz E, Marre R, Herhahn D, Sack K. 1985. The therapeutic response of cephalosporin-treated Escherichia coli pyelonephritis of the rat, in relation to variations of the infection model. Zentralbl Bakteriol Mikrobiol Hyg A 259:531\u2013537.","journal-title":"Zentralbl Bakteriol Mikrobiol Hyg A"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00959-17"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.11.008"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250600674436"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2016.36.5.489"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00105-X"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm476"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-16"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2013.06.010"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_3_24_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Cockerill FR","year":"2012","unstructured":"Cockerill FR, III, Wikler MA, Alder J, Dudley MN, Eliopoulos GM, Ferraro MJ, Hardy DJ, Hecht DW, Hindler JA, Patel JB, Powell M, Swenson JM, Thomson RB, Jr, Traczewski MM, Turnidge JD, Weinstein MP, Zimmer BL. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_25_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 17th informational supplement","author":"Cockerill FR","year":"2012","unstructured":"Cockerill FR, III, Wikler MA, Alder J, Dudley MN, Eliopoulos GM, Ferraro MJ, Hardy DJ, Hecht DW, Hindler JA, Patel JB, Powell M, Swenson JM, Thomson RB, Jr, Traczewski MM, Turnidge JD, Weinstein MP, Zimmer BL. 2012. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2256"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01884-13"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00086-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00086-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:38:26Z","timestamp":1645479506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00086-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1128\/AAC.00086-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00086-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2019-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00086-19"}}